Micronized progesterone reduces vasoconstriction in the placenta

References

• Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84
   PubMed Web of Science ®Google Scholar
• Steer P. The epidemiology of preterm labour. BJOG 2005;112:1–3
   PubMed Web of Science ®Google Scholar
• da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
   PubMed Web of Science ®Google Scholar
• Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 2008;112:127–34
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85
   PubMed Web of Science ®Google Scholar
• O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687–96
   PubMed Web of Science ®Google Scholar
• DeFranco EA, O'Brien JM, Adair CD, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697–705
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31
   PubMed Web of Science ®Google Scholar
• Steer PJ. The epidemiology of preterm labour – why have advances not equated to reduced incidence? BJOG 2006;113:1–3
   PubMed Web of Science ®Google Scholar
• Anderson L, Martin W, Higgins C, et al. The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy. Reprod Sci 2009;16:1052–61
   PubMed Web of Science ®Google Scholar
• Kuon RJ, Shi SQ, Maul H, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol 2010;202:455
   PubMed Web of Science ®Google Scholar
• Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485–90
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Diamond MP, Abuzeid M. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer. Fertil Steril 2010;93:554–69
   PubMed Web of Science ®Google Scholar
• Ruddock NK, Shi SQ, Jain S, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008;199:391
   PubMed Web of Science ®Google Scholar
• Fonseca E, Yu CK, Singh M, et al. Relationship between second-trimester uterine artery Doppler and spontaneous early preterm delivery. Ultrasound Obstet Gynecol 2006;27:301–5
   PubMed Web of Science ®Google Scholar
• Murphy JG, Khalil RA. Decreased [Ca(2±)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 1999;291:44–52
   PubMed Web of Science ®Google Scholar
• Strigini FA, Lencioni G, De Luca G, et al. Uterine artery velocimetry and spontaneous preterm delivery. Obstet Gynecol 1995;85:374–77
   PubMed Web of Science ®Google Scholar
• Arias F, Rodriquez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynecol 1993;168:585–91
   PubMed Web of Science ®Google Scholar
• Arias F, Victoria A, Cho K, Kraus F. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol 1997;89:265–71
   PubMed Web of Science ®Google Scholar
• Salafia CM, Vogel CA, Vintzileos AM, et al. Placental pathologic findings in preterm birth. Am J Obstet Gynecol 1991;165:934–38
   PubMed Web of Science ®Google Scholar
• Challis JR, Fraher L, Oosterhuis J, et al. Fetal and maternal endocrine responses to prolonged reductions in uterine blood flow in pregnant sheep. Am J Obstet Gynecol 1989;160:926–32
   PubMed Web of Science ®Google Scholar
• Sug-Tang A, Bocking AD, Brooks AN, et al. Effects of restricting uteroplacental blood flow on concentrations of corticotrophin-releasing hormone, adrenocorticotrophin, cortisol, and prostaglandin E2 in the sheep fetus during late pregnancy. Can J Physiol Pharmacol 1992;70:1396–402
   PubMed Web of Science ®Google Scholar
• Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol 2004;191:1063–69
   PubMed Web of Science ®Google Scholar
• Paonessa DJ, Shields AD, Howard BC, et al. 17-Hydroxyprogesterone caproate reverses induced vasoconstriction of the fetoplacental arteries by the thromboxane mimetic U46619. Am J Obstet Gynecol 2006;195:1011–14
   PubMed Web of Science ®Google Scholar
• Zelig CM, Paonessa DJ, Hoeldtke NJ, et al. Continuous infusion of 17-hydroxyprogesterone caproate into either the fetoplacental or intervillous circulation of a placental cotyledon attenuates vasoconstriction of the fetoplacental arteries by thromboxane mimetic U46619. Am J Obstet Gynecol 2010;202:189 e181–85
   Web of Science ®Google Scholar
• Glance DG, Elder MG, Myatt L. The actions of prostaglandins and their interactions with angiotensin II in the isolated perfused human placental cotyledon. Br J Obstet Gynaecol 1986;93:488–94
   PubMedGoogle Scholar
• Markenson GR, Foley K, Maslow AS, Kopelman JN. The effects of atrial natriuretic factor and angiotensin II on fetal-placental perfusion pressure in the ex vivo cotyledon model. Am J Obstet Gynecol 1995;173:1143–47
   PubMed Web of Science ®Google Scholar
• Napolitano PG, Hoeldtke NJ, Moore KH, et al. The fetoplacental pressor effects of low-dose acetylsalicylic acid and angiotensin II in the ex vivo cotyledon model. Am J Obstet Gynecol 1997;177:1093–96
   PubMed Web of Science ®Google Scholar
• Cudeville C, Mondon F, Robert B, et al. Evidence for progesterone receptors in the human fetoplacental vascular tree. Biol Reprod 2000;62:759–65
   PubMed Web of Science ®Google Scholar
• Challis JR, Sloboda DM, Alfaidy N, et al. Prostaglandins and mechanisms of preterm birth. Reproduction 2002;124:1–17
   PubMed Web of Science ®Google Scholar